A5056422254- Monoclonal and Polyclonal Antibodies Research
- Rheumatoid Arthritis Research and Therapies
- Cardiomyopathy and Myosin Studies
- Advanced Drug Delivery Systems
- Muscle Physiology and Disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Glycosylation and Glycoproteins Research
- T-cell and B-cell Immunology
- HIV/AIDS drug development and treatment
Pfizer (United States)
2022-2024
Brigham and Women's Hospital
2018
Abstract Local delivery of therapeutics for the treatment inflammatory arthritis (IA) is limited by short intra-articular half-lives. Since IA severity often fluctuates over time, a local drug method that titrates release to activity would represent an attractive paradigm in therapy. Here we report development hydrogel platform exhibits disassembly and controlled concentration enzymes expressed during flares. In vitro, loaded with triamcinolone acetonide (TA) releases on-demand upon exposure...
This study has employed mammalian transient expression systems to generate afucosylated antibodies and antibody Fc mutants for rapid candidate screening in discovery early development. While chemical treatment with the fucose analogue 2-fluoro-peracetyl-fucose during only partially produced N-glycans, genetic inactivation of FUT8 gene ExpiCHO-S™ by CRISPR/Cas9 enabled production fully antibodies. Human IgG1 murine IgG2a generated ExpiCHOfut8KO cell line possessed a 8-to-11-fold enhanced...
α-dystroglycanopathies are congenital muscular dystrophies in which genetic mutations cause the decrease or absence of a unique and complex O-linked glycan called matriglycan. This hypoglycosylation matriglycan on α-dystroglycan (α-DG) protein subunit abolishes reduces binding to extracellular ligands such as laminins skeletal muscles, leading compromised survival muscle cells after contraction.